By Ian Walker

LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Monday it has started a triple combination therapy phase III study for the treatment of asthma with Innoviva Inc. (INVA).

The study will investigate the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol compared to therapy with the once-daily dual combination therapy, Relvar/Breo(R) (FF/VI).

Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

(END) Dow Jones Newswires

December 19, 2016 04:56 ET (09:56 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Innoviva Charts.
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Innoviva Charts.